Value & Access
Achieving successful launch, reimbursement and uptake of new therapeutics and technologies
We support pharmaceutical, biotech and medtech companies in demonstrating value, securing reimbursement and bringing treatments successfully to market. From early commercial input through to evaluation and reimbursement, our team has delivered inside industry, government and health systems.
The challenge
Demonstrating value in an increasingly demanding environment
Getting a new medicine to market has never been more demanding. Health technology assessment (HTA) bodies, national payers and integrated health systems around the world apply increasingly rigorous evidence standards. Pricing negotiations are more complex. The window between regulatory approval and meaningful commercial uptake is narrowing - and the cost of getting the access strategy wrong from the start has never been higher.
Pharmaceutical, biotech and medtech companies are under mounting pressure to build stronger evidence packages, engage payers earlier, and create value narratives that hold up under scrutiny - across multiple markets, simultaneously.
Our approach
Unrivalled expertise, built from deep experience
Our Value & Access team is led by people who have held executive roles in industry and health systems.
Berkeley Greenwood has over 30 years of experience and has supported more than 600 products through successful NICE evaluation. Blake Dark spent 25 years in industry before serving as the NHS's chief negotiator with the pharmaceutical sector. Rob Kettell has held senior positions at HM Treasury, DHSC and NHS England on life sciences policy and negotiation. Professor Peter Clark is a global clinical leader in oncology and former Chair of the NHS Cancer Drugs Fund. That depth of direct experience shapes every engagement.
We apply it practically — from defining your value proposition and shaping your evidence strategy to managing HTA submissions and navigating commercial negotiations with payers and health systems. Our advice is candid, strategic and grounded in what actually works.
What we do
Market access and value strategy across the full innovation lifecycle
Our support spans the complete market access value chain — from early stage commercial input and pipeline reviews through to reimbursement, launch and uptake. We provide both strategic advice and hands-on technical delivery.
Pipeline reviews
Clinical, commercial and healthcare system assessment across a portfolio — identifying where to invest and how to sequence.
Launch strategy
Assessment of payer evidence requirements and commercial expectations, and development of a multi-market pricing and access strategy taking account of international reference pricing dynamics.
HTA submission
End-to-end management of technology appraisals — from scoping
and dossier development through to committee and appeal.
Commercial negotiation
Preparation and support for payer commercial negotiations or procurement exercises — drawing on direct experience of how this engagement works from both sides.
Adoption and uptake
Building the clinical case for adoption, engaging local commissioners, and developing the tools that field teams need to drive usage across health systems.
how we work
From value strategy to successful market uptake
We begin where your evidence and commercial strategy intersect — identifying the gaps, stress-testing the assumptions, and building the foundations that a successful reimbursement case requires. Our team stays with you through the process, not just the planning.
Stress test your value proposition
We bring a highly experienced clinical and health system perspective to your pipeline and launch decisions: ensuring a robust value story and supporting effective prioritisation.
Support effective payer engagement
We ensure you are prepared to engage effectively through the market access process: drawing on our deep experience across industry, HTA, and payer organisations to coach and support you through the reimbursement system.
Develop bespoke commercial strategies
We develop innovative commercial models to unlock payer negotiation, support HTA approvals, and maintain lifecycle value: finding creative solutions which are grounded in our experience of heath system realities.
Ensure local & lasting access
National reimbursement is just the start. We help navigate local health systems, engaging commissioners and key partners to turn decisions into real-world patient access.
The outcome
Faster access. Stronger reimbursement. Lasting impact.
Our clients describe our advice as unmatched in terms of understanding government and NHS system thinking. That's not coincidence — it's the result of building a team that has operated at the highest levels of the systems our clients are trying to navigate.
Products taken through successful NICE evaluation
Years of market access & HTA expertise in our senior leadership
Senior specialists across market access, policy and evidence analytics
Our team
Actionable advice from people who understand the market
Newmarket Strategy brings together market access specialists, healthcare policy experts, clinicians, analysts and commercial strategists.
Related case studies
Continue reading
What we do
Pillars of our expertise
Newmarket Strategy has industry-leading expertise supporting market access strategy through policy, reimbursement and evidence synthesis.
Value & Access
Empowering organisations to set commercial strategy, demonstrate value and secure reimbursement.
Global Health Policy & Government Affairs
Helping organisations navigate complex political landscapes, influence decision makers, and shape health policy.
Health Economics & Evidence Synthesis
Harnessing robust data and economic modelling to build a compelling evidence base and drive market uptake.
